全球危重肢体缺血治疗市场研究报告 - 2023 年至 2030 年行业分析、规模、份额、增长、趋势和预测

全球危重肢体缺血治疗市场需求预计将从 2022 年的 50.5 亿美元增至 2030 年的近 132.7 亿美元，2023-2030 年研究期间复合年增长率为 11.33%。

严重肢体缺血是指 PAD（外周动脉疾病）的晚期阶段。严重肢体缺血的治疗通常包括预防血栓、降低血压和降低胆固醇的药物，或使用其中一根静脉或合成替代物修復或更换动脉的手术。此外，有时还可能包括血管内治疗。所有这些方法都旨在恢復患者手脚的正常血流，以减少需要截肢的机会。

市场动态：

推动严重肢体缺血市场的主要因素包括严重肢体缺血患病率的增长和丰富的产品线。此外，采用有前景的治疗策略（例如最佳血运重建）也有望扩大全球危重肢体缺血治疗市场。血管内和最佳血运重建技术的进步是关键的肢体缺血治疗市场趋势。此外，改善血运重建结果并重点减少缺血相关心血管危险因素的需求为行业参与者提供了良好的机会。

该研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对全球严重肢体缺血治疗市场的各个细分市场进行了包容性评估。严重肢体缺血治疗行业的增长和趋势为本研究提供了整体方法。

区域分析：

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲的严重肢体缺血治疗市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。危重肢体缺血治疗市场的主要参与者包括波士顿科学公司、Cesca Therapeutics Inc.、Abbott Laboratories、Pluristem Therapeutics Inc.、Rexgenero Ltd、LimFlow SA、Micro Medical Solutions、心血管系统公司。竞争格局，包括各种战略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何定制要求，请写信给我们。我们的研究团队可以根据您的需求提供定制报告。

目录

第一章：前言

• 报告说明
  • 客观的
  • 目标受众
  • 独特的销售主张 (USP) 和产品
• 研究范围
• 研究方法论
  • 市场研究过程
  • 市场研究方法论

第 2 章：执行摘要

• 市场亮点
• 全球市场概况

第 3 章：严重肢体缺血治疗 - 行业分析

• 简介 - 市场动态
• 市场驱动因素
• 市场限制
• 机会
• 行业动态
• 波特五力分析
• 市场吸引力分析
  • 按处理方式进行的市场吸引力分析
  • 市场吸引力分析：按地区

第 4 章：价值链分析

• 价值链分析
• 原材料分析
  • 原材料清单
  • 原料厂商清单
  • 主要原材料价格走势
• 潜在买家名单
• 营销渠道
  • 直效行销
  • 间接营销
  • 营销渠道发展趋势

第 5 章：COVID-19 爆发的影响分析

第 6 章：全球危重肢体缺血治疗市场分析：按治疗分类

• 按治疗概述
• 历史和预测数据
• 按治疗分析
• 药物（抗血小板药、抗高血压药、降脂药、抗血栓药、其他）
• 器械（栓塞防护装置、外周扩张系统、球囊扩张器、血管支架）

第 7 章：全球危重肢体缺血治疗市场分析：按地理位置

• 区域展望
• 介绍
• 北美销售分析
  • 概述、历史和预测销售分析
  • 北美按细分市场销售分析
  • 北美按国家/地区销售分析
  • 美国销售分析
  • 加拿大销售分析
  • 墨西哥销售分析
• 欧洲销售分析
  • 概述、历史和预测销售分析
  • 欧洲按细分市场销售分析
  • 欧洲按国家/地区销售分析
  • 英国销售分析
  • 法国销售分析
  • 德国销售分析
  • 意大利销售分析
  • 俄罗斯销售分析
  • 欧洲其他地区销售分析
• 亚太地区销售分析
  • 概述、历史和预测销售分析
  • 亚太地区按细分市场销售分析
  • 亚太地区国家/地区销售分析
  • 中国销售分析
  • 印度销售分析
  • 日本销售分析
  • 韩国销售分析
  • 澳大利亚销售分析
  • 亚太地区其他地区销售分析
• 拉丁美洲销售分析
  • 概述、历史和预测销售分析
  • 拉丁美洲按细分市场销售分析
  • 拉丁美洲按国家/地区销售分析
  • 巴西销售分析
  • 阿根廷销售分析
  • 秘鲁销售分析
  • 智利销售分析
  • 拉丁美洲其他地区销售分析
• 中东和非洲销售分析
  • 概述、历史和预测销售分析
  • 中东和非洲按细分市场销售分析
  • 中东和非洲国家销售分析
  • 沙特阿拉伯销售分析
  • 阿联酋销售分析
  • 以色列销售分析
  • 南非销售分析
  • 中东其他地区和非洲销售分析

第 8 章：严重肢体缺血治疗公司的竞争格局

• 严重肢体缺血治疗市场竞争
• 伙伴关係/协作/协议
• 併购
• 新产品发布
• 其他发展

第 9 章：公司简介

• 顶级公司市场份额分析
• 市场集中度
• Boston Scientific Corporation
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Cesca Therapeutics Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Abbott Laboratories
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Pluristem Therapeutics Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Rexgenero Ltd
• 公司简介
• 公司收入
• 产品
• 最近的发展
• LimFlow SA
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Micro Medical Solutions
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Cardiovascular Systems Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展

注意 - 在公司概况中，财务详细信息和近期发展视情况而定，或者如果是私营公司，则可能不包括在内

The global demand for Critical Limb Ischemia Treatment Market is presumed to reach the market size of nearly USD 13.27 BN by 2030 from USD 5.05 BN in 2022 with a CAGR of 11.33% under the study period 2023 - 2030.

Critical limb ischemia refers to an advanced stage of PAD (Peripheral Arterial Disease). The treatment for critical limb ischemia generally includes medications to prevent clots, reduce blood pressure and lower cholesterol, or surgery to repair or replace an artery using one of the veins or a synthetic replacement. Further, it may, at times, also include endovascular treatments. All these methods aim to restore proper blood flow to the patient's hands and feet to reduce the chances of needing an amputation.

MARKET DYNAMICS:

Major factors boosting the critical limb ischemia market include growth in the prevalence of critical limb ischemia and a rich product pipeline. Further, the adoption of promising therapeutic strategies such as optimal revascularization is also expected to augment the global critical limb ischemia treatment market. Advancements in endovascular and optimal revascularization techniques are key critical limb ischemia treatment market trends. Moreover, the need for improving the outcomes of revascularization with a focus on reducing ischemia-associated cardiovascular risk factors offers a good opportunity for the industry players.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of critical limb ischemia treatment. The growth and trends of critical limb ischemia treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the critical limb ischemia treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment

• Medication (Antiplatelet Drugs, Antihypertensive Agents, Lipid-Lowering Agents, Antithrombotic Agents, Others)
• Devices (Embolic Protection Devices, Peripheral Dilatation System, Balloon Dilators, Vascular Stents)

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Critical Limb Ischemia Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the critical limb ischemia treatment market include Boston Scientific Corporation, Cesca Therapeutics Inc., Abbott Laboratories, Pluristem Therapeutics Inc., Rexgenero Ltd, LimFlow SA, Micro Medical Solutions, Cardiovascular Systems Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . CRITICAL LIMB ISCHEMIA TREATMENT - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Treatment
  • 3.7.2 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET ANALYSIS BY TREATMENT

• 6.1 Overview by Treatment
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Treatment
• 6.4 Medication (Antiplatelet Drugs, Antihypertensive Agents, Lipid-lowering Agents, Antithrombotic Agents, Others) Historic and Forecast Sales by Regions
• 6.5 Devices (Embolic Protection Devices, Peripheral Dilatation System, Balloon Dilators, Vascular Stents) Historic and Forecast Sales by Regions

7 . GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1. Overview, Historic and Forecast Sales Analysis
  • 7.3.2. North America By Segment Sales Analysis
  • 7.3.3. North America By Country Sales Analysis
  • 7.3.4. United State Sales Analysis
  • 7.3.5. Canada Sales Analysis
  • 7.3.6. Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1. Overview, Historic and Forecast Sales Analysis
  • 7.4.2. Europe by Segment Sales Analysis
  • 7.4.3. Europe by Country Sales Analysis
  • 7.4.4. United Kingdom Sales Analysis
  • 7.4.5. France Sales Analysis
  • 7.4.6. Germany Sales Analysis
  • 7.4.7. Italy Sales Analysis
  • 7.4.8. Russia Sales Analysis
  • 7.4.9. Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1. Overview, Historic and Forecast Sales Analysis
  • 7.5.2. Asia Pacific by Segment Sales Analysis
  • 7.5.3. Asia Pacific by Country Sales Analysis
  • 7.5.4. China Sales Analysis
  • 7.5.5. India Sales Analysis
  • 7.5.6. Japan Sales Analysis
  • 7.5.7. South Korea Sales Analysis
  • 7.5.8. Australia Sales Analysis
  • 7.5.9. Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1. Overview, Historic and Forecast Sales Analysis
  • 7.6.2. Latin America by Segment Sales Analysis
  • 7.6.3. Latin America by Country Sales Analysis
  • 7.6.4. Brazil Sales Analysis
  • 7.6.5. Argentina Sales Analysis
  • 7.6.6. Peru Sales Analysis
  • 7.6.7. Chile Sales Analysis
  • 7.6.8. Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1. Overview, Historic and Forecast Sales Analysis
  • 7.7.2. Middle East & Africa by Segment Sales Analysis
  • 7.7.3. Middle East & Africa by Country Sales Analysis
  • 7.7.4. Saudi Arabia Sales Analysis
  • 7.7.5. UAE Sales Analysis
  • 7.7.6. Israel Sales Analysis
  • 7.7.7. South Africa Sales Analysis
  • 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE CRITICAL LIMB ISCHEMIA TREATMENT COMPANIES

• 8.1. Critical Limb Ischemia Treatment Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9 . COMPANY PROFILES OF CRITICAL LIMB ISCHEMIA TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. Boston Scientific Corporation
  • 9.3.1. Company Overview
  • 9.3.2. Company Revenue
  • 9.3.3. Products
  • 9.3.4. Recent Developments
• 9.4. Cesca Therapeutics Inc.
  • 9.4.1. Company Overview
  • 9.4.2. Company Revenue
  • 9.4.3. Products
  • 9.4.4. Recent Developments
• 9.5. Abbott Laboratories
  • 9.5.1. Company Overview
  • 9.5.2. Company Revenue
  • 9.5.3. Products
  • 9.5.4. Recent Developments
• 9.6. Pluristem Therapeutics Inc.
  • 9.6.1. Company Overview
  • 9.6.2. Company Revenue
  • 9.6.3. Products
  • 9.6.4. Recent Developments
• 9.7. Rexgenero Ltd
  • 9.7.1. Company Overview
  • 9.7.2. Company Revenue
  • 9.7.3. Products
  • 9.7.4. Recent Developments
• 9.8. LimFlow SA
  • 9.8.1. Company Overview
  • 9.8.2. Company Revenue
  • 9.8.3. Products
  • 9.8.4. Recent Developments
• 9.9. Micro Medical Solutions
  • 9.9.1. Company Overview
  • 9.9.2. Company Revenue
  • 9.9.3. Products
  • 9.9.4. Recent Developments
• 9.10. Cardiovascular Systems Inc.
  • 9.10.1. Company Overview
  • 9.10.2. Company Revenue
  • 9.10.3. Products
  • 9.10.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Treatment (USD MN)
• Medication (Antiplatelet Drugs, Antihypertensive Agents, Lipid-lowering Agents, Antithrombotic Agents, Others) Market Sales by Geography (USD MN)
• Devices (Embolic Protection Devices, Peripheral Dilatation System, Balloon Dilators, Vascular Stents) Market Sales by Geography (USD MN)
• Global Critical Limb Ischemia Treatment Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Critical Limb Ischemia Treatment Report
• Market Research Process
• Market Research Methodology
• Global Critical Limb Ischemia Treatment Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Treatment
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Treatment (USD MN)
• Medication (Antiplatelet Drugs, Antihypertensive Agents, Lipid-lowering Agents, Antithrombotic Agents, Others) Market Sales by Geography (USD MN)
• Devices (Embolic Protection Devices, Peripheral Dilatation System, Balloon Dilators, Vascular Stents) Market Sales by Geography (USD MN)
• Global Market by Revenue
• North America Market by Revenue
• Europe Market by Revenue
• Asia Pacific Market by Revenue
• Latin America Market by Revenue
• Middle East & Africa Market by Revenue
• Recent Development in Industry
• Top Companies Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.